Search

Brivanib Alaninate is a novel chiral prodrug possessing two stereogenic centers. Simultaneous HPLC separation of five isomers of Brivanib Alaninate was systematically investigated on a wide variety of polysaccharide-based chiral stationary phases (CSPs) using underivatization and pre-column derivatization methods. The influence of derivatizing groups and mobile phase composition on the enantioseparation and retention behavior of Brivanib Alaninate compounds was studied. To better understand the chiral recognition mechanism, the temperature effect was also evaluated. The results of these studies led to the first complete HPLC resolution of all five isomers of Brivanib Alaninate as carbobenzyloxy (CBZ) derivatives on a cellulose benzoate CSP (OJ-H).

Substituted biphenyl I (BMS-207940), a selective antagonist of the endothelin A (ETA) receptor, has been proposed for the treatment of congestive heart failure. The structure of I possesses a stereogenic axis due to the hindered rotation about the biphenyl bond in the presence of its large ortho-substituents. As a result, I exhibits atropisomerism in which two nonplanar, axially enantiomers exist, which will be generically referred to as isomers A and B. Within the pharmaceutical industry, both from a scientific and regulatory point of view, characterization of enantiomeric drugs has become an important step in the development process. To investigate the configurational stability of I atropisomers, normal phase enantiomeric LC with tandem UV and laser polarimetric detection was used under pseudo-physiological conditions: first in a simple aqueous medium at 37 degrees C, and then in human serum at 37 degrees C. Kinetic studies indicated that the half-life of I enantiomerization in an aqueous medium at 37 degrees C was ca. 15 h. Enantiomerization of I atropisomers was greatly accelerated in the presence of human serum and human serum albumin, and the rate of enantiomerization depended on the concentration of I. The sera-concentration-dependent enantiomerization behavior of I strongly suggests a restricted site-specific substrate/I interaction mechanism. It was therefore demonstrated that atropisomeric interconversion studies for the compound studied required consideration of temperature, presence of plasma proteins, and drug concentration to account for the kinetic data.

For further insight into the role of solvent in protein conformer stabilization, the structural and dynamic properties of protein ions in vacuo have been probed by hydrogen-deuterium exchange in a Fourier-transform mass spectrometer. Multiply charged ions generated by electrospray ionization of five proteins show exchange reactions with 2H2O at 10(-7) torr (1 torr = 133.3 Pa) exhibiting pseudo-first-order kinetics. Gas-phase compactness of the S-S cross-linked RNase A relative to denatured S-derivatized RNase A is indicated by exchange of 35 and 135 hydrogen atoms, respectively. For pure cytochrome c ions, the existence of at least three distinct gaseous conformers is indicated by the substantially different values--52, 113, and 74--of reactive H atoms; the observation of these same values for ions of a number--2, 7, and 5, respectively--of different charge states indicates conformational insensitivity to coulombic forces. For each of these conformers, the compactness in vacuo indicated by these values corresponds directly to that of a known conformer structure in the solution from which the conformer ions are produced by electrospray. S-derivatized RNase A ions also exist as at least two gaseous conformers exchanging 50-140 H atoms. Gaseous conformer ions are isometrically stable for hours; removal of solvent greatly increases conformational rigidity. More specific ion-molecule reactions could provide further details of conformer structures.